Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Official title: An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo
In brief: This is a multicenter, open-label study designed to evaluate the safety, tolerability and efficacy of ATI-50002 Topical Solution 0.46% in subjects with non-segmental facial vitiligo. Subjects will be required to have a clinical diagnosis of non-segmental facial vitiligo effecting at least 0.25% of total body surface area (TBSA) (excluding upper and lower eyelids, mucosal lip areas, and forehead and chin areas covered by the stereotactic positioning device for photography) with at least one area of the face with normal pigmentation. Twenty-four eligible subjects will receive ATI-50002 Topical Solution, 0.46%, BID for 24 weeks.
Ages eligible: 18 Years to 65 Years
Locations: Aclaris Investigator Site
- Encinitas, California, United States, 92024
- Los Angeles, California, United States, 90036
- Worcester, Massachusetts, United States, 01655
- Dallas, Texas, United States, 75390
- Lynchburg, Virginia, United States, 24501
Status: Unknown, not recruiting
Start date: March 19, 2018
Completion date: September 30, 2019
Identifier: ClinicalTrials.gov NCT03468855
Contacts: To learn more about this study, you or your doctor may contact Aclaris Therapeuitcs. Please refer to this study by its NCT number.
- I have vitiligo: will my children have vitiligo, too?
Children born to parents who both have the disorder are more likely to develop vitiligo. However, most children will not get vitiligo even if one parent has it. In children wit...
- Will it spread?
Vitiligo activity may vary considerably from person to person. In a good number of patients the disease goes on for 3-4 years and then it settles down, with one or two stubborn...
- Who is prone to vitiligo?
Scientists know that some people are genetically predisposed to a specific group of autoimmune diseases – including generalized vitiligo – but do not know who and why.It doesn’t...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.